← Oncology Approval Tracker

FDA DECISION ·

Onureg

azacitidine · Celgene

FDA approvalNew formulationAcute myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Continued treatment for adults with acute myeloid leukemia in first complete remission, with or without incomplete count recovery, after intensive induction chemotherapy who could not complete intensive curative therapy.

LAMPGEN ANALYSIS

Why it matters

Established oral maintenance in this remission setting with a formulation distinct from injectable azacitidine.

What research teams should watch

Do not substitute injectable azacitidine; reconcile the cycle schedule and plan serial blood counts.

PRIMARY RECORDS

Sources